Gallant Therapeutics, a San Diego, CA-based animal health biotechnology company pioneering off-the-shelf stem cell therapies for pets, closed its Series A financing, securing over $15m.
The round was led by BOLD Capital and joined by new investors Digitalis Ventures and Hill Creek Partners. Cindy Cole of Digitalis Ventures will join as a board observer alongside a new independent director who will join existing board members Teymour Boutros-Ghali, Linda Black, Richard Jennings, Darryl Rawlings, and James Ratigan Sr.
The funding round will enable Gallant to accelerate the development of its pipeline of potentially first-in-class allogeneic stem cell therapeutics, focusing on achieving conditional FDA approval for its leading therapeutic candidate targeting FCGS, a deadly disease with a high unmet medical need. Beyond FCGS, Gallant is advancing a pipeline that targets osteoarthritis (OA), chronic kidney disease (CKD), and atopic dermatitis— all chronic diseases with a high burden of care in dogs and cats.
Led by Linda Black, DVM, Ph.D., CEO, Gallant Therapeutics is a clinical-stage biotechnology company setting a new standard in animal health by delivering a pipeline of off-the-shelf stem cell therapies that target the root cause of major diseases in pets.
FinSMEs
08/01/2023